Literature DB >> 3262882

The response of patients with purulent bronchiectasis to antibiotics for four months.

S L Hill1, D Burnett, K A Hewetson, R A Stockley.   

Abstract

Continuous treatment with antibiotics for 16 weeks was given to 10 patients with bronchiectasis who regularly produced purulent elastase positive secretions. Macroscopic clearance of secretions (from purulent to mucoid or mucopurulent) was achieved in all patients, and this was associated with a significant reduction in the average sputum elastase content by week 16 (p less than 0.001) when elastase was only detectable in three of the patients. Lung inflammation was also reduced as reflected in the sputum to serum albumin ratios. In addition patients noted a significant improvement in well being, and breathlessness as well as in sputum colour and volume and there was a significant improvement in peak expiratory flow. After cessation of treatment the time taken for the sputum to become purulent again ranged from 15 days to 10 months (median 2.5 months), which is longer than that seen previously following short courses of antibiotic treatment. Serum levels of the acute phase protein alpha 1 antichymotrypsin fell by week 16, although this failed to reach statistical significance. However, in eight patients where data were available the levels rose significantly after treatment had finished. The concentrations were consistently higher than those seen in healthy controls, and were also elevated in less severely affected patients suggesting that bronchiectasis is always associated with some systemic effect.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3262882

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  7 in total

1.  Symptom resolution assessed using a patient directed diary card during treatment of acute exacerbations of chronic bronchitis.

Authors:  I S Woolhouse; S L Hill; R A Stockley
Journal:  Thorax       Date:  2001-12       Impact factor: 9.139

2.  Presence, activities, and molecular forms of cathepsin G, elastase, alpha 1-antitrypsin, and alpha 1-antichymotrypsin in bronchiectasis.

Authors:  R Sepper; Y T Konttinen; T Ingman; T Sorsa
Journal:  J Clin Immunol       Date:  1995-01       Impact factor: 8.317

Review 3.  Severe bronchiectasis.

Authors:  Brian M Morrissey; Samuel J Evans
Journal:  Clin Rev Allergy Immunol       Date:  2003-12       Impact factor: 8.667

4.  Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi-centre randomized controlled trial.

Authors:  Patricia C Valery; Peter S Morris; Keith Grimwood; Paul J Torzillo; Catherine A Byrnes; I Brent Masters; Paul A Bauert; Gabrielle B McCallum; Charmaine Mobberly; Anne B Chang
Journal:  BMC Pediatr       Date:  2012-08-14       Impact factor: 2.125

Review 5.  Prolonged antibiotics for non-cystic fibrosis bronchiectasis in children and adults.

Authors:  Khin Hnin; Chau Nguyen; Kristin V Carson; David J Evans; Michael Greenstone; Brian J Smith
Journal:  Cochrane Database Syst Rev       Date:  2015-08-13

6.  Brazilian consensus on non-cystic fibrosis bronchiectasis.

Authors:  Mônica Corso Pereira; Rodrigo Abensur Athanazio; Paulo de Tarso Roth Dalcin; Mara Rúbia Fernandes de Figueiredo; Mauro Gomes; Clarice Guimarães de Freitas; Fernando Ludgren; Ilma Aparecida Paschoal; Samia Zahi Rached; Rosemeri Maurici
Journal:  J Bras Pneumol       Date:  2019-08-12       Impact factor: 2.624

Review 7.  Head-to-head trials of antibiotics for bronchiectasis.

Authors:  Axel Kaehne; Stephen J Milan; Lambert M Felix; Emer Sheridan; Paul A Marsden; Sally Spencer
Journal:  Cochrane Database Syst Rev       Date:  2018-09-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.